Hemostemix Inc. (CVE:HEM – Get Free Report) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.06 and traded as low as C$0.06. Hemostemix shares last traded at C$0.06, with a volume of 24,000 shares changing hands.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.24 and a debt-to-equity ratio of -66.09. The firm has a 50 day moving average price of C$0.06 and a 200 day moving average price of C$0.07. The stock has a market cap of C$11.27 million, a P/E ratio of -2.75 and a beta of 0.18.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Articles
- Five stocks we like better than Hemostemix
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
